Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?

1 Jan 2011

Abstract excerpt

Myelodysplastic syndrome (MDS) represents a heterogeneous group of diseases with clonal proliferation, bone marrow failure and increasing risk of transformation into an acute myeloid leukaemia. Structured guidelines are developed for selective therapy based on prognostic subgroups, age, and performance status. Although many driving forces of disease phenotype and biology are described, the complete and possibly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21629744
DOI: 10.1155/2011/214143

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?PMID 21629744Read ↗

Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid LeukemiasSemantic proximity Read ↗

Epigenetics in myeloid malignancies.Semantic proximity Read ↗

Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.Semantic proximity Read ↗

The myelodysplastic syndrome as a prototypical epigenetic diseaseSemantic proximity Read ↗

The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia.Semantic proximity Read ↗

Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes.Semantic proximity Read ↗

Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase InhibitorsSemantic proximity Read ↗

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related diseaseSemantic proximity Read ↗

Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.Semantic proximity Read ↗

The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformationsSemantic proximity Read ↗

Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemiaSemantic proximity Read ↗

The epigenomics revolution in myelodysplasia: a clinico-pathological perspective.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.